IMMIX BIOPHARMA, INC. Shareholders' Equity
IMMIX BIOPHARMA, INC. (IMMX) had Shareholders' Equity of $228.92 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-07
- 2026-06-30: Stockholders' Equity Attributable to Parent $228.92M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $84.36M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $93.80M.
- 2025-06-30: Stockholders' Equity Attributable to Parent $4.65M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $228.92M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $84.36M 10-Q · filed 2026-08-07 |
| 2025-12-31 | $93.80M 10-Q · filed 2026-08-07 |
| 2025-06-30 | $4.65M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $9.59M 10-Q · filed 2026-08-07 |
| 2024-12-31 | $13.25M 10-Q · filed 2026-08-07 |
| 2024-09-30 | $17.55M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $23.89M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $27.92M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $16.41M 10-K · filed 2025-03-25 |
| 2023-09-30 | $19.77M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $13.23M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $11.77M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $13.16M 10-K · filed 2024-03-29 |
| 2022-09-30 | $16.75M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $18.11M 10-Q · filed 2022-11-09 |
| 2022-03-31 | $19.65M 10-Q · filed 2022-11-09 |
| 2021-12-31 | $17.99M 10-Q · filed 2022-11-09 |
| 2021-09-30 | -$6.20M 10-Q · filed 2022-11-09 |
| 2021-06-30 | -$5.85M 10-Q · filed 2022-11-09 |
| 2021-03-31 | -$5.71M 10-Q · filed 2022-11-09 |
| 2020-12-31 | -$4.73M 10-Q · filed 2022-11-09 |
| 2019-12-31 | -$3.65M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |